These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24340560)

  • 1. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials.
    Karpiuk I; Tyski S
    Przegl Epidemiol; 2013; 67(3):455-60, 557-61. PubMed ID: 24340560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Looking for the new preparations for antibacterial therapy. I. New antibiotics and chemotherapeutics on the market].
    Karpiuk I; Tyski S
    Przegl Epidemiol; 2012; 66(4):567-73. PubMed ID: 23484382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials.
    Karpiuk I; Tyski S
    Przegl Epidemiol; 2015; 69(4):723-9, 865-70. PubMed ID: 27139351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors.
    Karpiuk I; Tyski S
    Przegl Epidemiol; 2013; 67(1):51-6, 135-40. PubMed ID: 23745376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the quinolones.
    Andersson MI; MacGowan AP
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():1-11. PubMed ID: 12702698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interscience Conference on Antimicrobial Agents and Chemotherapy--47th Annual Meeting. New antimicrobial agents: Part 1. 17-20 September 2007, Chicago, IL, USA.
    Din S
    IDrugs; 2007 Nov; 10(11):751-4. PubMed ID: 17968749
    [No Abstract]   [Full Text] [Related]  

  • 10. MS-209 Schering.
    Robert J
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
    Appelbaum PC; Jacobs MR
    Curr Opin Microbiol; 2005 Oct; 8(5):510-7. PubMed ID: 16098786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
    Xicota MA; Coll R; Esteve M; Moros M; Parés J
    Drugs Exp Clin Res; 1987; 13(3):133-6. PubMed ID: 3622242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interscience Conference on Antimicrobial Agents and Chemotherapy--47th Annual Meeting. New antimicrobial agents: Part 2. 17-20 September 2007, Chicago, IL, USA.
    Cleverley J
    IDrugs; 2007 Nov; 10(11):755-8. PubMed ID: 17968750
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmid-mediated quinolone resistance--current knowledge and future perspectives.
    Guan X; Xue X; Liu Y; Wang J; Wang Y; Wang J; Wang K; Jiang H; Zhang L; Yang B; Wang N; Pan L
    J Int Med Res; 2013 Feb; 41(1):20-30. PubMed ID: 23569126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking inventory: antibacterial agents currently at or beyond phase 1.
    Bush K; Macielag M; Weidner-Wells M
    Curr Opin Microbiol; 2004 Oct; 7(5):466-76. PubMed ID: 15451501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New agents in development for the treatment of bacterial infections.
    Abbanat D; Morrow B; Bush K
    Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Place of quinolones in the therapeutic armoury.
    Van Klingeren B
    Pharm Weekbl Sci; 1986 Feb; 8(1):40-1. PubMed ID: 3960692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
    Farrell DJ; Turner LL; Castanheira M; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for bacterial urinary tract infections.
    Wagenlehner FM; Weidner W; Naber KG
    Expert Opin Emerg Drugs; 2005 May; 10(2):275-98. PubMed ID: 15934867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.